TELA Bio, Inc. - Common stock (TELA)

Competitors to TELA Bio, Inc. - Common stock (TELA)

C.R. Bard (BD) 

C.R. Bard, now part of Becton Dickinson, is a well-established leader in the surgical devices market and competes with TELA Bio through its diversified product lines, including hernia repair products and implantable materials. Bard's extensive experience, R&D capabilities, and established customer relationships provide it with a significant competitive advantage. However, TELA Bio differentiates itself with its focus on bioengineered technologies that may offer better integration and healing, catering to specific surgical needs that allow it to compete effectively despite Bard's larger market share and resources.

Mimedx Group Inc 

Mimedx Group Inc specializes in regenerative medicine products, particularly in tissue allografts and wound care, making it a direct competitor to TELA Bio, which focuses on bioabsorbable implant technologies for soft tissue repairs. Both companies are involved in innovative solutions aimed at improving surgical outcomes and patient recovery. While Mimedx has a well-established presence in the regenerative tissue market, TELA's unique bioengineered products provide a competitive edge in specific surgical applications, particularly in hernia repair and soft tissue reconstruction.

Surgical Innovation Associates

Surgical Innovation Associates develops innovative surgical devices for soft tissue repair which directly overlaps with TELA Bio’s offerings. The two companies compete in the same market segment, with both focusing on enhancing surgical outcomes through advanced materials and surgical techniques. TELA, however, may hold a competitive advantage due to its proprietary bioabsorbable technologies that offer distinct performance benefits in terms of healing and patient recovery compared to some of the more traditional methods employed by Surgical Innovation Associates.

Suturo Medical

Suturo Medical engages in the development of advanced surgical solutions for diverse applications, making it a competitor to TELA Bio in the space of surgical implants and tissue repairs. Both companies aim to leverage innovative materials and engineering to improve patient outcomes. While Suturo may focus more broadly on surgical instruments, TELA's specialization in bioengineered implants gives it a competitive edge in niche markets such as hernia surgery, allowing TELA to establish strong partnerships with healthcare professionals in that specialty.